InnoCare raises $55M
InnoCare Pharma Ltd. (Beijing, China) raised $55 million in a financing led by Vivo Capital. Existing investor Shanghai CCB Principal Capital Management also participated.
InnoCare is developing through R&D and in-licensing a pipeline of immune-modulating therapies to treat autoimmune diseases and cancer. It has several candidates in clinical testing, including IPC-022.
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
Purchase this article for limited one-time distribution and website posting
$750 USD
